Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

(2016) Takamasa Ohki et al.   CLINICAL DRUG INVESTIGATION

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

(2016) L.A. Leiter et al.   DIABETES & METABOLISM

Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention

(2016) Eduardo Vilar-Gomez et al.   HEPATOLOGY

The independent predictors of non-alcoholic steatohepatitis and its individual histological features.

(2016) Stefano Ballestri et al.   HEPATOLOGY RESEARCH

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats

(2016) Norihisa Nishimura et al.   JOURNAL OF GASTROENTEROLOGY

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

(2016) Chikara Komiya et al.   PLoS One

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

(2015) Yuka Hayashizaki-Someya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:post hocsubgroup analyses according to body mass index in a 52-week open-label study

(2015) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2015) Sumio Watanabe et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

(2014) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients

(2014) Yuya Seko et al.   HEPATOLOGY RESEARCH

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study

(2014) Nobuya Inagaki et al.   Journal of Diabetes Investigation

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

(2013) N. Inagaki et al.   DIABETES OBESITY & METABOLISM

Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

(2013) Takashi Nakahara et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

(2010) Nathalie C. Leite et al.   LIVER INTERNATIONAL